{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:49:52Z","timestamp":1793836192675,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-023-05190-y","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T09:50:11Z","timestamp":1694685011000},"page":"5191-5202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study"],"prefix":"10.1007","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8603-4230","authenticated-orcid":false,"given":"Yael","family":"Levy-Shraga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravit","family":"Regev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Gal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avivit","family":"Brener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Lebenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Strich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amnon","family":"Zung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Cleper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Borovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Zadik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Davidovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Zeitlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dov","family":"Tiosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"5190_CR1","doi-asserted-by":"publisher","unstructured":"Baroncelli GI, Mora S (2021) X-linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management. Front Endocrinol (Lausanne) 12:688309. https:\/\/doi.org\/10.3389\/fendo.2021.688309","DOI":"10.3389\/fendo.2021.688309"},{"issue":"7","key":"5190_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15(7):435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"key":"5190_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bone.2016.11.013","volume":"100","author":"OM Kuro","year":"2017","unstructured":"Kuro OM, Moe OW (2017) FGF23-alphaKlotho as a paradigm for a kidney-bone network. Bone 100:4\u201318. https:\/\/doi.org\/10.1016\/j.bone.2016.11.013","journal-title":"Bone"},{"issue":"6","key":"5190_CR4","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/bcp.13763","volume":"85","author":"EA Imel","year":"2019","unstructured":"Imel EA, White KE (2019) Pharmacological management of X-linked hypophosphataemia. Br J Clin Pharmacol 85(6):1188\u20131198. https:\/\/doi.org\/10.1111\/bcp.13763","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"5190_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00467-010-1705-9","volume":"26","author":"M Zivicnjak","year":"2011","unstructured":"Zivicnjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U et al (2011) Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 26(2):223\u2013231. https:\/\/doi.org\/10.1007\/s00467-010-1705-9","journal-title":"Pediatr Nephrol"},{"issue":"Suppl 2","key":"5190_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12325-019-01178-z","volume":"37","author":"F Santos Rodriguez","year":"2020","unstructured":"Santos Rodriguez F (2020) X-linked hypophosphataemic rickets and growth. Adv Ther 37(Suppl 2):55\u201361. https:\/\/doi.org\/10.1007\/s12325-019-01178-z","journal-title":"Adv Ther"},{"issue":"4","key":"5190_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00467-011-2046-z","volume":"27","author":"C Quinlan","year":"2012","unstructured":"Quinlan C, Guegan K, Offiah A, Neill RO, Hiorns MP, Ellard S et al (2012) Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol 27(4):581\u2013588. https:\/\/doi.org\/10.1007\/s00467-011-2046-z","journal-title":"Pediatr Nephrol"},{"issue":"18","key":"5190_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJM198010303031802","volume":"303","author":"FH Glorieux","year":"1980","unstructured":"Glorieux FH, Marie PJ, Pettifor JM, Delvin EE (1980) Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med 303(18):1023\u20131031. https:\/\/doi.org\/10.1056\/NEJM198010303031802","journal-title":"N Engl J Med"},{"key":"5190_CR9","doi-asserted-by":"publisher","unstructured":"Uday S, Shaw NJ, Mughal MZ, Randell T, Hogler W, Santos R et al (2021) Monitoring response to conventional treatment in children with XLH: value of ALP and Rickets Severity Score (RSS) in a real world setting. Bone 151:116025. https:\/\/doi.org\/10.1016\/j.bone.2021.116025","DOI":"10.1016\/j.bone.2021.116025"},{"issue":"8","key":"5190_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.3544","volume":"33","author":"M Collins","year":"2018","unstructured":"Collins M (2018) Burosumab: at long last, an effective treatment for FGF23-associated hypophosphatemia. J Bone Miner Res 33(8):1381\u20131382. https:\/\/doi.org\/10.1002\/jbmr.3544","journal-title":"J Bone Miner Res"},{"issue":"4","key":"5190_CR11","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM et al (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 124(4):1587\u20131597. https:\/\/doi.org\/10.1172\/JCI72829","journal-title":"J Clin Invest"},{"issue":"7","key":"5190_CR12","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T et al (2015) Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100(7):2565\u20132573. https:\/\/doi.org\/10.1210\/jc.2015-1551","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"5190_CR13","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, Hogler W, Linglart A et al (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378(21):1987\u20131998. https:\/\/doi.org\/10.1056\/NEJMoa1714641","journal-title":"N Engl J Med"},{"issue":"3","key":"5190_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J et al (2019) Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7(3):189\u2013199. https:\/\/doi.org\/10.1016\/S2213-8587(18)30338-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10189","key":"5190_CR15","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393(10189):2416\u20132427. https:\/\/doi.org\/10.1016\/S0140-6736(19)30654-3","journal-title":"Lancet"},{"issue":"5","key":"5190_CR16","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","volume":"108","author":"R Padidela","year":"2021","unstructured":"Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O et al (2021) Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif Tissue Int 108(5):622\u2013633. https:\/\/doi.org\/10.1007\/s00223-020-00797-x","journal-title":"Calcif Tissue Int"},{"key":"5190_CR17","doi-asserted-by":"publisher","first-page":"204201882110011","DOI":"10.1177\/20420188211001150","volume":"12","author":"A Brener","year":"2021","unstructured":"Brener A, Lebenthal Y, Cleper R, Kapusta L, Zeitlin L (2021) Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy. Ther Adv Endocrinol Metab 12:20420188211001150. https:\/\/doi.org\/10.1177\/20420188211001150","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"5190_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jpc.15976","volume":"58","author":"JL Sandy","year":"2022","unstructured":"Sandy JL, Simm PJ, Biggin A, Rodda CP, Wall CL, Siafarikas A et al (2022) Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab. J Paediatr Child Health 58(5):762\u2013768. https:\/\/doi.org\/10.1111\/jpc.15976","journal-title":"J Paediatr Child Health"},{"issue":"Pt 2","key":"5190_CR19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1177\/000456329803500203","volume":"35","author":"RB Payne","year":"1998","unstructured":"Payne RB (1998) Renal tubular reabsorption of phosphate (TmP\/GFR): indications and interpretation. Ann Clin Biochem 35(Pt 2):201\u2013206. https:\/\/doi.org\/10.1177\/000456329803500203","journal-title":"Ann Clin Biochem"},{"issue":"11","key":"5190_CR20","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1093\/ndt\/gfab331","volume":"37","author":"L Derain Dubourg","year":"2022","unstructured":"Derain Dubourg L, Aurelle M, Chardon L, Flammier S, Lemoine S, Bacchetta J (2022) Tubular phosphate handling: references from child to adulthood in the era of standardized serum creatinine. Nephrol Dial Transplant 37(11):2150\u20132156. https:\/\/doi.org\/10.1093\/ndt\/gfab331","journal-title":"Nephrol Dial Transplant"},{"key":"5190_CR21","doi-asserted-by":"publisher","first-page":"1018523","DOI":"10.3389\/fendo.2022.1018523","volume":"13","author":"V Brescia","year":"2022","unstructured":"Brescia V, Fontana A, Lovero R, Capobianco C, Marsico SV, De Chirico T et al (2022) Determination of iFGF23 upper reference limits (URL) in healthy pediatric population, for its better correct use. Front Endocrinol (Lausanne) 13:1018523. https:\/\/doi.org\/10.3389\/fendo.2022.1018523","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"5190_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","volume":"46","author":"TD Thacher","year":"2000","unstructured":"Thacher TD, Fischer PR, Pettifor JM, Lawson JO, Manaster BJ, Reading JC (2000) Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr 46(3):132\u2013139. https:\/\/doi.org\/10.1093\/tropej\/46.3.132","journal-title":"J Trop Pediatr"},{"key":"5190_CR23","doi-asserted-by":"publisher","unstructured":"Thacher TD, Pettifor JM, Tebben PJ, Creo AL, Skrinar A, Mao M et al (2019) Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic Rickets Severity Score. Bone. 122:76\u201381. Epub 2019\/02\/18. https:\/\/doi.org\/10.1016\/j.bone.2019.02.010","DOI":"10.1016\/j.bone.2019.02.010"},{"issue":"6","key":"5190_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1515\/jpem-2020-0734","volume":"34","author":"D Harada","year":"2021","unstructured":"Harada D, Ueyama K, Oriyama K, Ishiura Y, Kashiwagi H, Yamada H et al (2021) Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets. J Pediatr Endocrinol Metab 34(6):791\u2013798. https:\/\/doi.org\/10.1515\/jpem-2020-0734","journal-title":"J Pediatr Endocrinol Metab"},{"key":"5190_CR25","doi-asserted-by":"publisher","first-page":"1034580","DOI":"10.3389\/fendo.2022.1034580","volume":"13","author":"MZ Mughal","year":"2022","unstructured":"Mughal MZ, Baroncelli GI, de Lucas-Collantes C, Linglart A, Magnolato A, Raimann A et al (2022) Burosumab for X-linked hypophosphatemia in children and adolescents: opinion based on early experience in seven European countries. Front Endocrinol (Lausanne) 13:1034580. https:\/\/doi.org\/10.3389\/fendo.2022.1034580","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"5190_CR26","doi-asserted-by":"publisher","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","volume":"107","author":"LM Ward","year":"2022","unstructured":"Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, Hogler W et al (2022) Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107(8):e3241\u2013e3253. https:\/\/doi.org\/10.1210\/clinem\/dgac296","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"5190_CR27","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1007\/s00467-022-05484-7","volume":"37","author":"NJ Paloian","year":"2022","unstructured":"Paloian NJ, Nemeth B, Sharafinski M, Modaff P, Steiner RD (2022) Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 37(11):2667\u20132677. https:\/\/doi.org\/10.1007\/s00467-022-05484-7","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"5190_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart A, Imel EA, Whyte MP, Portale AA, Hogler W, Boot AM et al (2022) Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107(3):813\u2013824. https:\/\/doi.org\/10.1210\/clinem\/dgab729","journal-title":"J Clin Endocrinol Metab"},{"key":"5190_CR29","doi-asserted-by":"publisher","unstructured":"Cagnoli M, Richter R, Bohm P, Knye K, Empting S, Mohnike K (2017) Spontaneous growth and effect of early therapy with calcitriol and phosphate in X-linked hypophosphatemic rickets. Pediatr Endocrinol Rev 15(Suppl 1):119\u201322. https:\/\/doi.org\/10.17458\/per.vol15.2017.crb.spontaneousgrowtheffect","DOI":"10.17458\/per.vol15.2017.crb.spontaneousgrowtheffect"},{"issue":"10","key":"5190_CR30","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1210\/clinem\/dgaa495","volume":"105","author":"M Mao","year":"2020","unstructured":"Mao M, Carpenter TO, Whyte MP, Skrinar A, Chen CY, San Martin J et al (2020) Growth curves for children with X-linked hypophosphatemia. J Clin Endocrinol Metab 105(10):3243\u20133249. https:\/\/doi.org\/10.1210\/clinem\/dgaa495","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"5190_CR31","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1210\/jc.2003-030036","volume":"88","author":"O Makitie","year":"2003","unstructured":"Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E (2003) Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 88(8):3591\u20133597. https:\/\/doi.org\/10.1210\/jc.2003-030036","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"5190_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1067\/mpd.2001.108955","volume":"138","author":"GI Baroncelli","year":"2001","unstructured":"Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G (2001) Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 138(2):236\u2013243. https:\/\/doi.org\/10.1067\/mpd.2001.108955","journal-title":"J Pediatr"},{"issue":"6","key":"5190_CR33","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1542\/peds.113.6.e593","volume":"113","author":"D Haffner","year":"2004","unstructured":"Haffner D, Nissel R, Wuhl E, Mehls O (2004) Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 113(6):e593\u2013e596. https:\/\/doi.org\/10.1542\/peds.113.6.e593","journal-title":"Pediatrics"},{"issue":"12","key":"5190_CR34","doi-asserted-by":"publisher","first-page":"E2097","DOI":"10.1210\/jc.2011-0399","volume":"96","author":"M Zivicnjak","year":"2011","unstructured":"Zivicnjak M, Schnabel D, Staude H, Even G, Marx M, Beetz R et al (2011) Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab 96(12):E2097\u2013E2105. https:\/\/doi.org\/10.1210\/jc.2011-0399","journal-title":"J Clin Endocrinol Metab"},{"key":"5190_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ghir.2017.08.001","volume":"36","author":"A Rothenbuhler","year":"2017","unstructured":"Rothenbuhler A, Esterle L, Gueorguieva I, Salles JP, Mignot B, Colle M et al (2017) Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). Growth Horm IGF Res 36:11\u201315. https:\/\/doi.org\/10.1016\/j.ghir.2017.08.001","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"5190_CR36","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00467-017-3820-3","volume":"33","author":"N Meyerhoff","year":"2018","unstructured":"Meyerhoff N, Haffner D, Staude H, Wuhl E, Marx M, Beetz R et al (2018) Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets. Pediatr Nephrol 33(3):447\u2013456. https:\/\/doi.org\/10.1007\/s00467-017-3820-3","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"5190_CR37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s13023-022-02590-5","volume":"17","author":"J Andre","year":"2022","unstructured":"Andre J, Zhukouskaya VV, Lambert AS, Salles JP, Mignot B, Bardet C et al (2022) Growth hormone treatment improves final height in children with X-linked hypophosphatemia. Orphanet J Rare Dis 17(1):444. https:\/\/doi.org\/10.1186\/s13023-022-02590-5","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"5190_CR38","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/s13023-022-02562-9","volume":"17","author":"DA Ertl","year":"2022","unstructured":"Ertl DA, Le Lorier J, Gleiss A, Trabado S, Bensignor C, Audrain C et al (2022) Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone. Orphanet J Rare Dis 17(1):412. https:\/\/doi.org\/10.1186\/s13023-022-02562-9","journal-title":"Orphanet J Rare Dis"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05190-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-023-05190-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-023-05190-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T00:10:38Z","timestamp":1699661438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-023-05190-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["5190"],"URL":"https:\/\/doi.org\/10.1007\/s00431-023-05190-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3071481\/v1","asserted-by":"object"}]},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"16 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved by the institutional review board of each individual medical center, with Sheba Medical Center as the primary site (approval number 5914-19-SMC). Written informed consent was not required by the ethics committee of Sheba Medical Center as the analysis did not use any identifying information of the individuals included in this retrospective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}